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Telephone: +44 (0) (1) . This results in raised pulmonary venous pressure and pulmonary 49 oedema, often leading to progressive pulmonary hypertension, right heart failure and 50 death. Development of a major venous collateral network can occur and may be 51 associated with improved outcome (1) . Neoproliferation of cells (2) is responsible for 52 the pulmonary venous narrowing but the exact pathophysiology remains unknown. 53
54
Our lack of understanding of this condition likely accounts for why there are so many 55 different types of surgical and catheter interventions; yet still we have not managed 56 to find the optimal treatment. Introduction of the "sutureless" surgical technique has 57 made some progress in treating proximal disease(3;4), but results remain 58 disappointing when there is distal disease. An aggressive, early combination of both 59 catheter and surgical interventional strategies may be the most effective, particularly 60 in young and small patients, where the disease process can be particularly active(5). 61
However, due to the progressive nature of pulmonary vein stenosis, the most 62 important prerequisite for successful outcome is to achieve complete abolition of the 63 stenosis at an early stage and before there is progression of the disease distally. The 64 optimal initial strategy is likely to depend upon local expertise, but repeated 65 interventions, both surgical and catheter should be contemplated. Mortality and 66 morbidity are substantial and even balloon angioplasty has recently been associated 67 with significant risk of neurological injury(6). as to why it helped remains unclear. There was no difference in TGF-β levels 140 between the losartan and non-losartan groups however there was a difference in VE-141 caderin levels which they thought was indicative of diminished endothelial integrity. 142
Clearly there is still much work to be done in establishing the pathological pathways 143 that lead to progressive distal venous obstruction and translating this to humans. 144
However, this is extremely exciting and innovative work investigating the potential for 145 post-interventional therapies to reduce the effect of distal disease. This would be 146 particularly important in patients considered at high risk of developing post-operative 147 stenosis. Lo Rito's imaging techniques may help identify such high risk groups and 148 monitor the effect of novel therapies. It would be extremely interesting to see 149 whether losartan has a role in reversing established disease and hopefully the 150 research team will go on to investigate this. Future work is likely to involve clinical 151 trials in humans and, due to the rarity of this disease; this is likely to be multi-152 institutional and multi-national. We sincerely hope that the paediatric cardiac 153 community can come together to make such trials a reality. 154
155
In summary, pulmonary vein stenosis is frequently a progressive disease leading to 156 generalised narrowing of the pulmonary veins and in some cases atresia. The best 157 way to prevent progression is to identify and treat the stenosis in the first place so 158 distal disease does not have the chance to occur. In this issue, the team from 159
Toronto proposes a new index of pulmonary vein cross sectional area measured at 160 cardiac magnetic resonance and computerised tomography as a tool to detect 161 patients that are likely to have distal disease and hence worse prognosis. They have 162 previously proposed losartan as a medical treatment which may have a role in 163 preventing distal disease from occurring. This is an exciting development which if 164 confirmed would represent a real advance in therapeutic options. So, are we at a 165 stage where we can prevent progression of pulmonary vein stenosis? There is no 166 doubt we are closer, however there is still much more work needed and clearly 167 collaborative medical trials are the optimal way to progress. For the present, 168 treatment of established distal pulmonary venous disease remains an extremely 169 challenging and resistant condition to treat. 170 171 172
